Has Nathan Trentham, MD received payments from drug or device companies?

Yes. Drug and device makers reported $404,376 in general payments to Nathan Trentham, MD across 1,527 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nathan Trentham, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nathan Trentham, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nathan Trentham, MD

Internal Medicine · Etowah, TNNPI 1134185358

Payments from drug & device makers

$404,376in general payments, 2019–2025

Across 1,527 payments — averaging $264.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$325K
Lilly USA, LLC$28K
Esperion Therapeutics, Inc.$17K
Sanofi-aventis U.S. LLC$10K
Merck$6K
Regeneron Healthcare Solutions, Inc.$4K
plus $13K from 52 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	564	$325,153
Lilly USA, LLC	160	$28,336
Esperion Therapeutics, Inc.	41	$17,280
Sanofi-aventis U.S. LLC	26	$10,117
Merck	19	$6,386
Regeneron Healthcare Solutions, Inc.	12	$4,418
Boehringer Ingelheim	39	$3,094
Novartis	146	$1,837
Novo Nordisk	85	$1,209
AbbVie(2 entities)	70	$904
Bayer	43	$660
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	34	$628
Pfizer	52	$585
AstraZeneca	35	$524
Johnson & Johnson	27	$384
Amarin Pharma, Inc.	20	$376
GSK	15	$228
Abbott	17	$228
Radius Health, Inc.	9	$157
Kowa Pharmaceuticals America, Inc.	10	$143
Xeris Pharmaceuticals, Inc.	8	$137
Takeda Pharmaceuticals U.S.A., Inc.	9	$132
Corcept Therapeutics	6	$127
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	8	$121
Biohaven Pharmaceutical Holding Company Ltd.	5	$94
Medtronic	5	$91
Eisai Inc.	6	$82
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	4	$78
Vifor Pharma, Inc.	3	$67
Heartflow, Inc.	2	$65
Biohaven Pharmaceuticals, Inc.	4	$61
Evoke Pharma, Inc.	4	$59
E.r. Squibb & Sons, L.L.C.	4	$55
Ironwood Pharmaceuticals, Inc	4	$51
Shire North American Group Inc	3	$38
Exact Sciences	2	$33
Boston Scientific	1	$30
Sunovion Pharmaceuticals Inc.	2	$30
Clarus Therapeutics Inc.	3	$29
Phathom Pharmaceuticals, Inc.	2	$29
Calliditas Therapeutics US Inc.	1	$25
Avanir Pharmaceuticals, Inc.	1	$24
Scpharmaceuticals Inc.	1	$23
Biogen	1	$20
Axsome Therapeutics, Inc.	1	$20
Regeneron	1	$19
Sumitomo Pharma America, Inc.	1	$19
Baxter Healthcare	1	$18
Otsuka America Pharmaceutical, Inc.	1	$17
Dynavax Technologies Corporation	1	$17
Acadia Pharmaceuticals Inc	1	$17
Chiesi USA, Inc.	1	$16
Antares Pharma, Inc.	1	$15
Inspire Medical Systems, Inc.	1	$15
Orthogenrx Inc.	1	$15
Astellas Pharma US Inc	1	$14
Teva Pharmaceuticals USA, Inc.	1	$13
Dexcom, Inc.	1	$12

How this compares

$404,376 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee →

Medicare billing

Part B allowed, 2024

$199,982

Medicare patients

424

Services billed

7,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Etowah

Mark McKenzieChattanooga$11.9M
Bernard GrunstraBristol$6.4M
Jewel WhiteKingsport$5.7M
Judith WhiteKingsport$5.6M
Obadias MarquezOoltewah$2.8M
Amanda Moore MillerKnoxville$2.3M
Rick WhilesBristol$1.5M
John AndersonNashville$1.5M
David MorinKingsport$1.4M
John KirbyJefferson City$1.2M

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →